|
| Tuesday, December 3, 2013 |
|
|
Cytokinetics Announces Closing of Enrollment Into BENEFIT-ALS, A Phase IIb Clinical Trial of Tirasemtiv in Patients with Amyotrophic Lateral Sclerosis |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced that the company has closed recruitment and enrollment of patients into BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS) with over 700 patients enrolled. more info >> |
|
| Monday, December 2, 2013 |
|
|
Cytokinetics Announces Presentation Relating to Tirasemtiv and BENEFIT-ALS at International Symposium on ALS/MND |
| Cytokinetics, (Nasdaq: CYTK) announced today that a presentation relating to tirasemtiv and BENEFIT-ALS, is scheduled to be presented at the 24th International Symposium on ALS/MND to be held December 6-8, 2013 at the Atahotel Quark in Milan, Italy. more info >> |
|
| Wednesday, November 27, 2013 |
|
|
Cytokinetics to Present at the 25th Annual Piper Jaffray Healthcare Conference |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the 25th Annual Piper Jaffray Healthcare Conference on December 3, 2013 at 9:30 AM Eastern Time at the New York Palace Hotel in New York, NY. more info >> |
|
| Thursday, October 31, 2013 |
|
|
Cytokinetics, Incorporated Reports Third Quarter 2013 Financial Results |
| Cytokinetics, Incorporated (Nasdaq: CYTK) reported total revenues for the third quarter of 2013 were $4.5 million, compared to $1.7 million during the same period in 2012. more info >> |
|
| Thursday, October 17, 2013 |
|
|
Cytokinetics to Announce Third Quarter Results on October 30, 2013 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it is scheduled to report third quarter results on Wednesday, October 30, 2013 at 4:00 PM Eastern Time. more info >> |
|
| Saturday, September 28, 2013 |
|
|
Cytokinetics to Present at the Leerink Swann Rare Disease Roundtable |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the Leerink Swann Rare Disease Roundtable on October 2, 2013 at 9:40 AM at Le Parker Meridien in New York, NY. more info >> |
|
| Tuesday, September 24, 2013 |
|
|
Cytokinetics Announces Presentation of Data from ATOMIC-AHF at Heart Failure Society of America Annual Scientific Meeting |
| Cytokinetics, Incorporated (NASDAQ:CYTK) today announced the presentation of additional data from the ATOMIC-AHF (Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure) clinical trial at a Late Breaking Clinical Trials Session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Orlando, Florida. more info >> |
|
| Thursday, September 5, 2013 |
|
|
Cytokinetics to Present at Healthcare Conferences in September |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the following healthcare conferences. more info >> |
|
| Friday, August 23, 2013 |
|
|
Cytokinetics Announces Publication of Results from Phase II Trials of Tirasemtiv in Patients with ALS |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced the publication of two manuscripts reporting data from two clinical trials of tirasemtiv, a novel mechanism fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis (ALS). more info >> |
|
| Thursday, August 15, 2013 |
|
|
Cytokinetics to Host Investor Event Following Presentation of Results from ATOMIC-AHF at the European Society of Cardiology Congress 2013 |
| Cytokinetics, Incorporated (Nasdaq: CYTK) announced today its plans to host an Investor Event following the presentation of the results from the ATOMIC-AHF trial at the European Society of Cardiology Congress 2013. more info >> |
|
|
|
|
